This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

To Evaluate the Efficacy and Safety of Vitamin B12 Contains Extract of Lamb's Stomach in Treatment of Chronic Atrophic Gastritis (CAG)

This study has been completed.
Information provided by (Responsible Party):
Xinjiang Biochemical Pharmaceutical Co., Ltd. Identifier:
First received: October 27, 2011
Last updated: July 6, 2013
Last verified: July 2013
The purpose of this study is to determine whether Gastropyloric Complex Capsules are safe and effective in the treatment of chronic atrophic gastritis (CAG).

Condition Intervention Phase
Chronic Atrophic Gastritis (CAG) Drug: Gastropylor Complex Capsules Other: Placebo Comparator Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Phase IV Study to Evaluate the Efficacy and Safety of Vitamin B12 Contains Extract of Lamb's Stomach in Treatment of Chronic Atrophic Gastritis

Resource links provided by NLM:

Further study details as provided by Xinjiang Biochemical Pharmaceutical Co., Ltd.:

Primary Outcome Measures:
  • Effective rate confirmed by histology [ Time Frame: within 180 days after treatment ]
    All patients are required to repeat the histology examination after 180 days follow-up is completed.

Secondary Outcome Measures:
  • clinical manifestations including abdominal pain, anorexia, nausea, vomiting, and belching [ Time Frame: within 180 days after treatment ]

Enrollment: 851
Study Start Date: August 2011
Study Completion Date: February 2013
Primary Completion Date: February 2013 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Placebo Comparator: Placebo Other: Placebo Comparator
Placebo that is same as gastropyloric complex capsules
Other Name: Placebo
Active Comparator: Gastropyloric Complex Capsules Drug: Gastropylor Complex Capsules
3 pills, three times a day, after meal
Other Name: Gastropyloric Extracts and Vit B12 Complex Capsules

Detailed Description:
Till now, there is no ideal treatment to chronic atrophic gastritis(CAG). This study is try to find a possible treatment to CAG with Gastropyloric Complex Capsules.

Ages Eligible for Study:   18 Years to 70 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Age 18-70 years, male or female
  • Histologically diagnosed CAG
  • HP negative confirmed by gastric mucosal staining
  • Signed an written informed consent

Exclusion Criteria:

  • CAG with high-grade intraepithelial neoplasia
  • Severe gastric mucosal erosion or bleeding needing treatment
  • Active peptic ulcer, GERD, or esophageal stricture
  • History of upper GI tract surgery
  • History of malignant diseases
  • With depression, anxiety neuroses, or hysteria
  • Heart failure (NYHA class lll or lV), liver disease (ALT ≥ 80 IU/L, AST ≥ 80 IU/L) or renal disease(Cr ≥ 150 ummol/L)
  • Uncontrolled hypertension
  • Uncontrolled diabetes
  • Alcohol abuse
  • Drug allergy
  • Participated in another investigational study within 4 weeks prior to Visit 0
  • Pregnancy, be a nursing mother or without conception control
  • There is any concern by the investigator regarding the safe participation of the participant in the study or for any other reason; the investigator considers the participant inappropriate for participation in the study
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01474044

China, Shanxi
Xijing Hospital of Digestive Diseases
Xi'an, Shanxi, China, 710032
Sponsors and Collaborators
Xinjiang Biochemical Pharmaceutical Co., Ltd.
Principal Investigator: Kaichun WU, Professor Xijing Hospital of Digestive Diseases
  More Information

Responsible Party: Xinjiang Biochemical Pharmaceutical Co., Ltd. Identifier: NCT01474044     History of Changes
Other Study ID Numbers: CATS-CO-002
Study First Received: October 27, 2011
Last Updated: July 6, 2013

Additional relevant MeSH terms:
Gastritis, Atrophic
Pathological Conditions, Anatomical
Gastrointestinal Diseases
Digestive System Diseases
Stomach Diseases
Vitamin B Complex
Vitamin B 12
Growth Substances
Physiological Effects of Drugs
Hematinics processed this record on September 21, 2017